Kyle Bass Claims Pink Sheet Article As Prior Art In Juxtapid Patent Challenge
This article was originally published in The Pink Sheet Daily
Executive Summary
University of Pennsylvania argues neither 2004 article nor slide presentation it describes constitutes prior art that would invalidate method of use claims.
You may also be interested in...
Aegerion’s Juxtapid Needs Long-term Post-Market Cohort Study After FDA Nod
Sponsor will institute a registry to monitor patients taking the LDL cholesterol-lowering drug for homozygous familial hypercholesterolemia for 10 years, as part of an approval that is a likely template for Genzyme’s Kynamro.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.